We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Analysis of Melanoma Exosomes Identifies Potential Relapse Risk

By LabMedica International staff writers
Posted on 22 Apr 2019
A team of Spanish cancer researchers demonstrated that it was possible to detect the BRAFV600E mutation in exudative seroma-derived extracellular vesicles of patients following melanoma surgery, and its detection correlated with the likelihood that the patients would relapse.

Investigators at the Centro Nacional de Investigaciones Oncológicas (Madrid, Spain) based their study on the premise that liquid biopsies from cancer patients could have the potential to improve diagnosis and prognosis and that assessment of surrogate markers of tumor progression in circulating extracellular vesicles could be a powerful non-invasive approach in this setting.

To this end, they characterized extracellular vesicles purified from the lymphatic drainage also known as exudative seroma (ES) of stage III melanoma patients obtained after lymphadenectomy. More...
Proteomic analysis showed that seroma-derived exosomes were enriched in proteins resembling melanoma progression.

Exosomes are cell-derived vesicles that are present in many and perhaps all biological fluids, including blood, urine, and cultured medium of cell cultures. The reported diameter of exosomes is between 30 and 100 nanometers, which is larger than low-density lipoproteins but much smaller than red blood cells. Exosomes, which contain RNA, proteins, lipids, and metabolites that are reflective of the cell type of origin, are either released from the cell when multivesicular bodies (MVBs) fuse with the plasma membrane, or they are released directly from the plasma membrane. Exosomes have specialized functions and play a key role in coagulation, intercellular signaling, and waste management.

In addition, the investigators found that the BRAFV600E mutation could be detected in ES-derived extracellular vesicles and its detection correlated with patients at risk of relapse.

"Our study has confirmed that, in melanoma patients, we can identify populations with higher risk of recurrence using a sensitive, accurate test of the exudative seroma," said senior author Dr. Héctor Peinado, head of the microenvironment and metastasis group at the Centro Nacional de Investigaciones Oncológicas. "Liquid biopsy applied to this seroma has revealed extracellular vesicles and circulating DNA with BRAF gene mutations associated with lower survival rates for melanoma patients. The method is performed in cooperation with clinical laboratories and could easily be applied in clinical practice. It only requires collecting seroma fluids and establishing the relevant protocol for collection, storage and analysis."

The study was published in the April 11, 2019, online edition of the Journal of Experimental Medicine.

Related Links:
Centro Nacional de Investigaciones Oncológicas


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple daily blood test could help critically ill sepsis patients stop antibiotics sooner, reducing overuse and potentially helping combat antibiotic resistance (Image Credit: Adobe Stock)

Daily Blood Biomarker Testing May Help Guide Earlier Antibiotic Stopping in Sepsis

Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The integration with FlexLab X brings the Panther System into fully tracked automation environments to increase capacity, traceability, and workflow efficiency (Photo courtesy of Hologic)

Hologic and Inpeco Partner to Advance Molecular Laboratory Automation in Europe

Hologic, Inc. (Marlborough, MA, USA) and Inpeco S.A. (Novazzano, Switzerland) have signed a co-marketing partnership in Europe for Inpeco’s recently launched FlexLab X automation solution and Hologic’s... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.